Shinda Biotechnology responds to the collection of biopharmaceuticals: the 200 billion performance target in 2027 already includes the impact of collection

Gate.io January 17 news, Chinese biopharmaceutical company Xinda Biotechnology (01801.HK) responded to the centralized procurement of biopharmaceuticals. Xinda Biotechnology stated that there are currently no more details about the specific list, rules, methods, and timing of the centralized procurement, and we will follow up to understand. The company currently has 14 products on the market, including 3 biosimilar drugs. This year, we will also launch rituximab, marstuximab, and pembrolizumab, so even if the centralized procurement is confirmed, the overall impact on Xinda will be limited. At the same time, the centralized procurement will also bring about a decrease in sales management expenses, so the impact on profits is also limited. In the long term, our target of 20 billion in 2027 will be achieved assuming the occurrence of centralized procurement and will not be affected.